Idelalisib Terminated Phase 2 Trials for B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02044822Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion